Consolidation Toripalimab
Phase 2Monoclonal antibody
Consolidation Toripalimab is one of 4 small molecule programs targeting Consolidation Therapy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Consolidation Therapy
#DrugCompanyPhaseTrials
1Epkinly
GenmabPhase 2
Sugemalimab
CCStone Pharmaceuticals
Phase 3
CD19 CAR-T Cells
CChongqing Precision Biotech Co., Ltd
Phase 2
Consolidation Toripalimab
SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Consolidation Toripalimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details